Schrödinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth
Schrodinger Inc. (NASDAQ:SDGR) is one of the best cancer stocks to invest in now. On February 25, Schrodinger Inc.
Schrodinger Inc. (SDGR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bill & Melinda Gates Foundation Trust Michael Larson | 6,981,664 | $124,832,152 | 0.35% | |
| 2. | Rubric Capital Management David Rosen | 4,171,498 | $74,586,384 | -21% | 0.89% |
| 3. | ARK Investment Management Catherine D. Wood | 2,111,829 | $37,759,501 | +13% | 0.25% |
| 4. | 1,357,900 | $24,279,252 | +25% | 0.04% | |
| 5. | Millennium Management Israel Englander | 978,172 | $17,489,715 | -37% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.90 | 1,115 | $111,385.94 | 0 | 2021-02-05 | Filing | |
| $17.00 | 588,235 | $9,999,995.00 | 6,981,664 | 2020-02-10 | Filing | |
| $17.00 | 250,000 | $4,250,000.00 | 250,000 | 2020-02-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.84 | 608 | $7,807.94 | 34,804 | 2026-03-06 | Filing | |
| $12.85 | 775 | $9,955.65 | 35,412 | 2026-03-05 | Filing | |
| $12.90 | 1,631 | $21,033.38 | 52,596 | 2026-03-05 | Filing | |
| $12.90 | 1,094 | $14,107.13 | 52,683 | 2026-03-05 | Filing | |
| $12.91 | 3,661 | $47,248.87 | 330,824 | 2026-03-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,075 | $151,409 | 0% | |
| 2. | 10,434 | $118,530 | 0.01% | |
| 3. | 4,316 | $49,030 | 0% | |
| 4. | 1,363 | $15,484 | 0% | |
| 5. | 941 | $10,869 | 0% |
News See All
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Schrödinger, Inc. (NASDAQ:SDGR) Q4 2025 Earnings Call Transcript
Operator: Thank you standing by. Welcome to Schrodinger's conference call to review fourth quarter and full year 2025 financial results. My name is Rob, and I'll be your operator for today's call.
BofA Upgrades Schrödinger (SDGR) to Buy After Strategic Pivot to Software
Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded Schrödinger, Inc.
11 Best Healthcare AI Stocks to Buy Now
On August 13, 2025, the World Economic Forum (WEF) published an analysis exploring how AI is transforming healthcare.
Schrödinger, Inc. (NASDAQ:SDGR) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to Schrodinger's conference call to review third quarter 2025 financial results. My name is Rob, and I'll be your operator for today's call.
Bill Gates’s Stock Portfolio: Top 15 Stock Picks
Bill Gates’s disciplined and long-term investment philosophy is reflected in the investment strategy of the Bill & Melinda Gates Foundation Trust, which manages the endowment supporting one of the world...
Schrödinger, Inc. (NASDAQ:SDGR) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to Schrodinger's conference call to review second quarter 2025 financial results. My name is Rob, and I'll be your operator for today's call.
Citi Affirms Buy Rating on Schrödinger (SDGR) amid Expanded Collaboration with Ajax Therapeutics
Schrödinger, Inc. (NASDAQ:SDGR) is one of the top 10 medical AI companies to buy according to analysts. On July 17, analysts at Citi reiterated a ‘Buy’ rating on the stock and a $39 price target.